TRACON Pharmaceuticals, Inc. (TCON): Rega marang bathi mangsa ngarep
The expected P/E multiple for TRACON Pharmaceuticals (TCON) reflects the impact of management's strategy regarding asset liquidation and the transparent winding down of operations. The value remains at 0.00, driven by the role of TRACON Pharmaceuticals (TCON) as an expert partner in clinical trials. This model helps biotech startups bring oncology drugs to market faster, filling the gap in effective therapy methods through collaboration with pharma behemoths.
TRACON Pharmaceuticals - rincian analitis lan metrik utama (TCON)
- kuotasi lan prakiraan analis:
- data kapitalisasi bursa:
- data ekuitas miturut neraca:
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas TRACON Pharmaceuticals|TCON - Kewajiban jangka dawa marang ekuitas|Utang jangka cendhak marang modal TRACON Pharmaceuticals, Inc.|TCON - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku TRACON|TCON - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan TRACON Pharmaceuticals|Likuiditas cepet traconpharma.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
TCON - Penghasilan resik|Proyeksi bathi mangsa ngarep TRACON Pharmaceuticals|TCON - Pangali P/E|Pangali Forward P/E traconpharma.com|TCON - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA TRACON Pharmaceuticals Inc.|TCON - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan TRACON Pharmaceuticals|TCON - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan traconpharma.com|TCON - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep TRACON Pharmaceuticals
- indikator pendapatan dodolan lan penghasilan bisnis:
Pambiji fundamental:TRACON Pharmaceuticals Inc.
For TRACON Pharmaceuticals, a leader in the development of targeted oncology drugs, the company's forward P/E ratio of 0.00 serves as an indicator of market expectations regarding the efficacy of clinical trials. This ratio is calculated by dividing the current share price by the projected annual net profit, allowing investors to determine the extent of the premium paid for future business growth and the risk of a "value trap."
Analisis perusahaan pesaing
Prakiraan rega marang bathi TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Pangali forward rega marang bathi|Rega marang bathi mangsa ngarep ionispharma.com IONS|Kapitalisasi marang proyeksi bathi Repligen Corporation (RGEN)|RNA: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi CRSP (CRISPR Therapeutics Corp)|WGS: Pangali Forward P/E|Rasio prakiraan rega marang bathi Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Pangali Forward P/E|SRPT: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Twist Bioscience Corp (TWST)|Prakiraan rega marang bathi 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi STOK|BLFS - Rega marang bathi mangsa ngarep|Wave Life Sciences (WVE) - Prakiraan rega marang bathi|MAZE: Pangali Forward P/E|Sionna Therapeutics, Inc. (SION) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Prime Medicine, Inc.|TSHA (Taysha) - Rasio kapitalisasi marang bathi mangsa ngarep|Prakiraan rega marang bathi QURE (uniQure Pharma)|Kapitalisasi marang proyeksi bathi meiragtx.com|Rega marang bathi mangsa ngarep REGENXBIO RGNX|SLDB - Prakiraan rega marang bathi|Ocugen, Inc. - Pangali Forward P/E|PACB (Pacific Biosciences of California) - Rasio rega marang bathi mangsa ngarep|BNTC: Pangali Forward P/E|DSGN - Kapitalisasi marang proyeksi bathi|RCKT (Rocket Pharma) - Pangali Forward P/E|Rega marang bathi mangsa ngarep FDMT|Rega marang bathi mangsa ngarep Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Rasio rega marang bathi mangsa ngarep|editasmedicine.com - Prakiraan rega marang bathi|Kapitalisasi marang proyeksi bathi silence-therapeutics.com (SLN)|PRQR: Prakiraan rega marang bathi|Rasio prakiraan rega marang bathi codexis.com|SGMO: Pangali Forward P/E|Rasio prakiraan rega marang bathi Nautilus Biotechnology Inc (NAUT)|Prakiraan rega marang bathi MGX|DTIL (Precision BioSciences) - Rasio kapitalisasi marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Generation Bio Corp (GBIO)|Boundless Bio - Rasio rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Exicure, Inc. XCUR|Pangali mangsa ngarep rega marang bathi IMNN|PHIO - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi Mustang Bio Inc MBIO|RNAZ: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep BNGO|APDN (Applied DNA Sciences Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Bluebird Bio BLUE|Pangali Forward P/E IPA|Omega Therapeutics (OMGA) - Pangali forward rega marang bathi|Pangali Forward P/E OMIC (Singular Genomics Systems Inc)|Pangali forward rega marang bathi Regulus Therapeutics Inc|SYRS - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi TBIO (Codex DNA)|UBX: Pangali Forward P/E
